|本期目录/Table of Contents|

[1]张海静 赵春晖 张文生.小檗碱治疗阿尔茨海默病研究进展[J].环球中医药,2017,10(06):663-667.[doi:10.3969/j.issn.1674-1749.2017.06.038]
　ZHANG Haijing,ZHAO Chunhui,ZHANG Wensheng..Research progress of berberine in treatment of Alzheimer's disease[J].,2017,10(06):663-667.[doi:10.3969/j.issn.1674-1749.2017.06.038]
点击复制

小檗碱治疗阿尔茨海默病研究进展()
     
分享到：

《环球中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
第10卷
期数:
2017年06期
页码:
663-667
栏目:
综述
出版日期:
2017-06-06

文章信息/Info

Title:
Research progress of berberine in treatment of Alzheimer's disease
作者:
张海静 赵春晖 张文生
100088 北京师范大学中药资源保护与利用北京市重点实验室[张海静(博士生)、赵春晖、张文生]; 教育部天然药物工程研究中心[张海静(博士生)、赵春晖、张文生]; 北京师范大学资源学院[张海静(博士生)、赵春晖、张文生]
Author(s):
ZHANG Haijing; ZHAO Chunhui; ZHANG Wensheng.
Beijing Area Major Laboratory of Protection and Utilization of Traditional Chinese Medicine, Beijing Normal University,100088 Beijing,China
关键词:
小檗碱;  阿尔茨海默病;  β-淀粉样蛋白;  神经保护;  糖脂代谢
Keywords:
Berberine;  Alzheimer's disease;  Amyloid β-protein;  Neuroprotection;  Glucolipid metabolism
分类号:
R749.1+6
DOI:
10.3969/j.issn.1674-1749.2017.06.038
文献标志码:
A
摘要:
阿尔茨海默病(Alzhermer'disease,AD)是一种以学习、记忆和认知功能障碍为主要表现的中枢神经系统退行性疾病。AD作为一种异质性的疾病,其致病机理复杂。小檗碱是一种常见的异喹啉类季铵生物碱,作为一种多靶点作用的药物对AD的病理具有一定的改善作用。包括改善认知能力、减少β淀粉样蛋白(β-amyloid,Aβ)产生、抑制Tau蛋白的过度磷酸化、抗炎、抗氧化、调节中枢神经递质代谢等。本文总结近年来小檗碱治疗AD的有关研究成果,以期为小檗碱防治AD提供借鉴。
Abstract:
Alzheimer's disease is a neurodegenerative disease of the central nervous system characterized by learning, memory and cognition deficit. AD is a heterogeneous disease, the pathogenesis is complex. Berberine is a common isoquinoline alkaloid, and as a multi-target therapeutic drug, it has the effect of improvement on AD. The functions of berberine include improving cognitive functioning, reducing Aβ level, reducing hyperphosphorylated Tau protein level,, anti-inflammatory, anti-oxidative stress, regulation of the neurotransmitter metabolism and so on. The recent research achievements of berberine in the treatment of AD are summarized in order to provide reference for the prevention and treatment of berberine in AD.

参考文献/References:

[1] Yao J,Kong W,Jiang J.Learning from berberine:Treating chronic diseases through multiple targets[J].Sci China Life Sci,2015,58(9):854.
[2] Wang X,Wang R,Xing D,et al.Kinetic difference of berberine between hippocampus and plasma in rat after intravenous administration of Coptidis rhizoma extract[J].Life Sci,2005,77(24):3058.
[3] Wang X,Xing D,Wang W,et al.Pharmacokinetics of berberine in rat thalamus after intravenous administration of Coptidis rhizoma extract[J].Am J Chin Med,2005,33(6):935.
[4] Durairajan S S,Liu L F,Lu J H,et al.Berberine ameliorates beta-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model[J].Neurobiol Aging,2012,33(12):2903.
[5] Zhu F,Qian C.Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1 beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease[J].BMC Neurosci,2006,7:78.
[6] Panahi N,Mahmoudian M,Mortazavi P,et al.Effects of berberine on beta-secretase activity in a rabbit model of Alzheimer's disease[J].Arch Med Sci,2013,9(1):146.
[7] Asai M,Iwata N,Yoshikawa A,et al.Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Abeta secretion[J].Biochem Biophys Res Commun,2007,352(2): 498.
[8] Zhu F,Wu F,Ma Y,et al.Decrease in the production of beta-amyloid by berberine inhibition of the expression of beta-secretase in HEK293 cells[J].BMC Neurosci,2011,12:125.
[9] 朱飞奇,马英,孙永安,等.小檗碱对阿尔茨海默病大鼠模型胰岛素降解酶表达的影响[J].中华神经医学杂志,2010,9(12):1201.
[10] Gong C X,Liu F,Grundke-Iqbal I,et al.Dysregulation of protein phosphorylation/ dephosphorylation in Alzheimer's disease: a therapeutic target[J].J Biomed Biotechnol,2006,2006,(3): 31825.
[11] Yu G,Li Y,Tian Q,et al.Berberine attenuates calyculin A-induced cytotoxicity and Tau hyperphosphorylation in HEK293 cells[J].J Alzheimers Dis,2011,24(3):525.
[12] Liu X,Zhou J,Abid M D,et al.Berberine attenuates axonal transport impairment and axonopathy induced by Calyculin A in N2a cells[J].PLoS One,2014,9(4): e93974.
[13] 许旌,张洪,杨帆,等.小檗碱对Aβ-(25-35)致SH-SY5Y细胞株炎症反应中TNF-α及Ⅰ型受体表达的干预作用[J].中国中药杂志,2013,38(9):1327.
[14] Jia L,Liu J,Song Z,et al.Berberine suppresses amyloid-beta-induced inflammatory response in microglia by inhibiting nuclear factor-kappaB and mitogen-activated protein kinase signalling pathways[J].J Pharm Pharmacol,2012,64(10):1510.
[15] Ji H F,Shen L.Berberine: a potential multipotent natural product to combat Alzheimer's disease[J].Molecules,2011,16(8):6732.
[16] Chen M,Tan M,Jing M,et al.Berberine protects homocysteic acid-induced HT-22 cell death: involvement of Akt pathway[J].Metab Brain Dis,2015,30(1):137.
[17] Munoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease[J]. Curr Med Chem, 2008, 15(24): 2433.
[18] Jung H A, Min B S, Yokozawa T, et al. Anti-Alzheimer and antioxidant activities of Coptidis Rhizoma alkaloids[J]. Biol Pharm Bull, 2009, 32(8): 1433.
[19] Ingkaninan K, Phengpa P, Yuenyongsawad S, et al. Acetylcholinesterase inhibitors from Stephania venosa tuber[J]. J Pharm Pharmacol, 2006, 58(5): 695.
[20] Huang L, Luo Z, He F, et al. Berberine derivatives, with substituted amino groups linked at the 9-position, as inhibitors of acetylcholinesterase/butyrylcholinesterase[J]. Bioorg Med Chem Lett, 2010, 20(22): 6649.
[21] Xiang J, Yu C, Yang F, et al. Conformation-activity studies on the interaction of berberine with acetylcholinesterase: Physical chemistry approach[J]. Progress in Natural Science, 2009, 19(12): 1721.
[22] Su T, Xie S, Wei H, et al. Synthesis and biological evaluation of berberine-thiophenyl hybrids as multi-functional agents: Inhibition of acetylcholinesterase, butyrylcholinesterase, and Abeta aggregation and antioxidant activity[J]. Bioorg Med Chem, 2013, 21(18): 5830.
[23] Shan W J,Huang L,Zhou Q,et al.Synthesis,biological evaluation of 9-N-substituted berberine derivatives as multi-functional agents of antioxidant,inhibitors of acetylcholinesterase,butyrylcholinesterase and amyloid-beta aggregation[J]. Eur J Med Chem, 2011, 46(12): 5885.
[24] Kong L D, Cheng C H, Tan R X. Monoamine oxidase inhibitors from rhizoma of Coptis chinensis[J]. Planta Med, 2001, 67(1): 74.
[25] Castillo J, Hung J, Rodriguez M, et al. LED fluorescence spectroscopy for direct determination of monoamine oxidase B inactivation[J]. Anal Biochem, 2005, 343(2): 293.
[26] Carradori S, D'Ascenzio M, Chimenti P, et al. Selective MAO-B inhibitors: a lesson from natural products[J]. Mol Divers, 2014, 18(1): 219.
[27] Yu C J, Zheng M F, Kuang C X, et al. Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2, 3-dioxygenase activity in vitro[J]. J Alzheimers Dis, 2010, 22(1): 257.
[28] Steen E, Terry B M, Rivera E J, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease—is this type 3 diabetes?[J]. J Alzheimers Dis, 2005, 7(1): 63.
[29] Whitmer R, Quesenberry Jr C, Allison J, et al. Anti-hyperglycemic therapy and risk of dementia: A new user cohort study[J]. Alzheimer's & Dementia, 2013, 9(4, Supplement): 136.
[30] Novak V, Milberg W, Hao Y, et al. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes[J]. Diabetes Care, 2014, 37(3): 751.
[31] Leng S H, Lu F E, Xu L J. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion[J]. Acta Pharmacol Sin, 2004, 25(4): 496.
[32] Lee Y S,Kim W S,Kim K H,et al.Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states[J].Diabetes,2006,55(8):2256.
[33] Turner N,Li J Y,Gosby A,et al.Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action[J].Diabetes,2008,57(5):1414.
[34] Xie X,Li W,Lan T,et al.Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway[J].Endocr J,2011,58(9):761.
[35] 陈广,陆付耳,王增四,等.小檗碱改善2型糖尿病大鼠胰岛素抵抗与PI-3K、GLUT4蛋白相关性的研究[J].中国药理学通报,2008,24(8):1007.
[36] Koudinov A R,Berezov T T,Koudinova N V.Cholesterol and Alzheimer's disease: is there a link[J].Neurology,2002,58(7):1135.
[37] Refolo L M,Pappolla M A,Lafrancois J,et al.A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease[J].Neurobiol Dis,2001,8(5): 890.
[38] Wolozin B.Cholesterol and the biology of Alzheimer's disease[J].Neuron,2004,41(1):7.
[39] Kong W,Wei J,Abidi P,et al.Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins[J].Nat Med,2004,10(12):1344.
[40] 师凌云,田蜜,常伟,等.小檗碱对脂质代谢相关基因PPARα和CPTIA表达的影响[J].中国药理学通报,2008,24(11):1461.
[41] Richardson K,Schoen M,French B,et al.Statins and cognitive function: a systematic review[J].Ann Intern Med,2013,159(10):688.

相似文献/References:

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金(81274118); 科技部“重大新药创制”科技重大专项(2012ZX09103-201); 中央高校基本科研业务费(2015KJJCA05)
作者简介: 张海静(1988- ),女,2014级在读博士研究生。研究方向:神经退行性疾病分子机制及神经药理学。E-mail:haijingzhang88@163.com
通信作者:张文生(1966- ),博士,教授,博士生导师。研究方向:中药神经药理及中药成分次生代谢。E-mail:zws@bnu.edu.cn
更新日期/Last Update: 2017-06-06